Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Targeting the CHD3 Chromatin Remodeler Exploits a Synthetic Lethal Vulnerability in SWI/SNF-Deficient Cancers via Toxic Derepression of PARD3B

ABSTRACT: SWI/SNF-deficient cancers characterized by dual SMARCA4/SMARCA2 loss, including undifferentiated thoracic sarcomas and subsets of lung adenocarcinoma, represent a major therapeutic challenge. While paralog-targeting strategies exist for single-subunit loss, dual-deficient tumors lack actionable targets. Here, we identify the CHD3/NuRD nucleosome remodeling complex as a critical synthetic lethal vulnerability in these malignancies. Through an integrated genomic analysis, we demonstrate that in the absence of SWI/SNF, CHD3 acts as an essential "epigenetic brake" at the enhancer of the cell polarity regulator PARD3B. Loss of CHD3 triggers aberrant chromatin hyper-accessibility and toxic derepression of PARD3B. We further elucidate that PARD3B accumulation drives cell death by inducing the "functional uncoupling" of MYC signaling. This occurs via spatial perturbation of upstream signaling hubs, which silences MYC transcriptional output without degrading the protein itself. Therapeutically, CHD3 depletion led to robust tumor regression in SWI/SNF-deficient xenografts, validating the mechanism of PARD3B upregulation and the collapse of the MYC pathway in vivo. Our study defines a novel mode of synthetic lethality driven by "gain-of-toxicity" rather than loss of survival signals, uncovering a fatal cross-complex dependency. We propose that targeting CHD3 to unleash PARD3B toxicity offers a promising therapeutic avenue for treatment-refractory SWI/SNF-deficient cancers.

ORGANISM(S): Homo sapiens

PROVIDER: GSE323137 | GEO | 2026/05/21

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma

Project description:Multiple myeloma (MM) is an incurable malignancy of plasma cells that exploits transcriptional networks driven by IRF4. To discover unique molecular vulnerabilities in MM centered on IRF4, we employ a multi-omics approach integrating functional genomics screening, spatial proteomics, and global chromatin mapping. We find that ARID1A, a member of the SWI/SNF chromatin remodeling complex, is both required for IRF4 expression and functionally associated with IRF4 protein on chromatin. Deletion of Arid1a in activated murine B cells thwarts subsequent plasma cell differentiation by disrupting IRF4-dependent transcriptional networks, therefore defining ARID1A as a novel plasma cell vulnerability. Targeting ARID1A-dependent SWI/SNF activity via SMARCA2/4 inhibition induces a rapid loss of IRF4-target gene expression and quenches global amplification of oncogenic gene expression driven by MYC, resulting in profound toxicity to MM cells. Notably, MM patients with aggressive disease have markers of SWI/SNF activity, and SMARCA2/4 inhibitors retain their activity in immunomodulatory drug (IMiD)-resistant MM cells. To fully harness the potential of these drugs, we use combinatorial drug screens to uncover profound synergistic toxicity between SMARCA2/4 and MEK inhibitors. Thus, targeting SWI/SNF activity potently represses an IRF4-MYC feed forward loop and provides a feasible path to effectively treat this incurable disease.

2024-01-11 | MSV000093842 | MassIVE

Multiple interactions of the oncoprotein transcription factor MYC with the SWI/SNF chromatin remodeler

Project description:We report that even though SNF5 is the most well-documented SWI/SNF subunit to bind MYC, MYC can use multiple interaction surfaces to interact with SWI/SNF subunits independently of SNF5. In line with this, MYC interacts with the pan-SWI/SNF subunit, BAF155, in multiple SNF5-null malignant rhabdoid tumor (MRT) cell lines and almost all of MYC co-localizes with SWI/SNF subunits on chromatin in MRT. In the MRT cell line, G401, MYC binds to essential genes, although for a purpose that appears distinct from chromatin remodeling, and loss of MYC leads to widespread gene expression changes. Analysis of specific MYC-SWI/SNF target genes in G401 cells reveals that this group of genes are associated with core biological functions linked to protein synthesis and their transcription is directly activated by MYC. These data provide a solid framework in which to interrogate the influence of SWI/SNF on MYC function in cancers in which SWI/SNF or MYC are altered.

2021-05-01 | GSE164926 | GEO

CHD3 regulates BMP signalling response during cranial neural crest cell specification

Project description:CHD3 is a component of the NuRD chromatin remodeller. Mutations in CHD3 cause Snijders Blok-Campeau Syndrome, a neurodevelopmental disorder marked by intellectual disability and craniofacial abnormalities. To unveil the role of CHD3 in craniofacial development, we differentiated CHD3-null induced pluripotent stem cells (iPSCs) into cranial neural crest cells (CNCC). We found that CHD3 expression is low in iPSCs and neuroectoderm, but it is upregulated during CNCC specification, where CHD3-containing NuRD opens the chromatin at BMP-responsive enhancers, to allow binding of DLX5 and other factors. CHD3 loss leads to repression of BMP target genes and imbalance between BMP and Wnt signalling, which ultimately results in aberrant mesodermal fate. Consequently, cranial neural crest specification fails, replaced by mesodermal identity, which can be partially rescued by titrating Wnt levels. Our findings highlight a novel role for CHD3 as pivotal regulator of BMP signalling, essential for proper neural crest specification and craniofacial development.

2025-02-05 | GSE288669 | GEO

IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma (ATAC-Seq human 8)

Project description:Multiple myeloma (MM) is an incurable malignancy of plasma cells that exploits transcriptional networks underpinning normal plasma cell biology to drive malignant growth and survival. The transcription factor IRF4 serves as the principal architect of plasma cell identity, and MM cells are addicted to IRF4 expression for their survival. To discover unique molecular vulnerabilities in MM, we employ a multi-omics approach integrating functional genomics screening, spatial-proteomics, and global chromatin mapping. We find that ARID1A, a member of the SWI/SNF chromatin remodeling complex, is both required for IRF4 expression and functionally associated with IRF4 protein on chromatin. Conditional deletion of Arid1a in activated murine B cells thwarts subsequent plasma cell differentiation by disrupting IRF4-dependent transcriptional networks, thus defining ARID1A as a novel plasma cell vulnerability. Targeting ARID1A-dependent SWI/SNF activity via SMARCA2/4 inhibition induces a rapid loss of IRF4-target gene expression and quenches global oncogenic amplification of gene expression driven by MYC, resulting in profound toxicity to MM cells. Notably, SWI/SNF-dependent genes are upregulated in MM patients with aggressive disease, and SMARCA2/4 inhibitors retain their activity in immunomodulatory drug (IMiD)-resistant MM cells. To fully harness the potential of these drugs, we use combinatorial drug screens to uncover profound synergistic toxicity between SMARCA2/4 and MEK inhibitors. Thus, targeting SWI/SNF activity potently represses an IRF4-MYC feed forward loop and provides a feasible path forward to effectively treat this incurable disease.

2024-05-01 | GSE253706 | GEO

IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma (CUT&RUN mouse 13)

2024-05-01 | GSE253712 | GEO

IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma (CUT&RUN human 6)

2024-05-01 | GSE253708 | GEO

IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma (CUT&RUN human 32)

2024-05-01 | GSE253707 | GEO

IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma (RNA-Seq human 16).

2024-05-01 | GSE253713 | GEO

IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma (CUT&RUN human 8).

2024-05-01 | GSE253711 | GEO

IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma (ATAC-Seq human 16)